Amgen Data From Phase 3 CANDOR Study Combining KYPROLIS® (carfilzomib) And DARZALEX® (daratumumab) To Be Presented During Late-Breaking Session At American Society Of Hematology Annual Meeting| Amgen
Amgen announced results from the Phase 3 CANDOR study showing that the combination of KYPROLIS and DARZALEX (KdD) reduced the risk of disease progression or death by 37% compared to KYPROLIS and dexamethasone alone (Kd) in relapsed or refractory multiple myeloma patients. The study met its primary endpoint of progression-free survival (PFS) and showed improvements in key secondary endpoints, including overall response rate and minimal residual disease.
How this was made
The 30-second read
Why it matters
The data provides a new treatment option with a clear PFS advantage, likely influencing market perception of Amgen's oncology pipeline.
Market read
First‑report of pivotal trial data that could move Amgen's stock and affect the broader oncology biotech sector.
What to watch
Potential safety concerns and higher adverse‑event rates in the combination arm may temper enthusiasm.
Background
Amgen announced additional Phase 3 CANDOR study results for its carfilzomib‑daratumumab regimen in relapsed/refractory multiple myeloma.
Ticker impact
Amgen disclosed Phase 3 CANDOR trial results showing a 37% reduction in progression risk (HR=0.63) and improved response rates.
likely upward pressure as investors price in improved efficacy and potential market expansion.
The trial met its primary endpoint with statistically significant PFS benefit and higher ORR, which typically lifts biotech stocks.
Market effects
Strengthens the multiple myeloma therapeutic landscape and may boost related biotech peers.
U.S. biotech sector could see modest gains on the back of the data.
Limited to oncology/biotech investors; no broad macro effect.
Counterpoint
If the data fails to translate into regulatory approval or commercial uptake, the rally could be short‑lived.
Key entities
- companyAmgen
US‑listed biotech firm (NASDAQ: AMGN) developing the KdD regimen.
- partnerJanssen
Co‑funded the CANDOR trial.
